Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesESRD and Chronic Dialysis
You have accessRestricted Access

Baseline Levels and Trimestral Variation of Triiodothyronine and Thyroxine and Their Association with Mortality in Maintenance Hemodialysis Patients

Christiaan L. Meuwese, Friedo W. Dekker, Bengt Lindholm, Abdul R. Qureshi, Olof Heimburger, Peter Barany, Peter Stenvinkel and Juan J. Carrero
CJASN January 2012, 7 (1) 131-138; DOI: https://doi.org/10.2215/CJN.05250511
Christiaan L. Meuwese
*Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands;
†Divisions of Renal Medicine, and Baxter Novum, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Friedo W. Dekker
*Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bengt Lindholm
†Divisions of Renal Medicine, and Baxter Novum, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdul R. Qureshi
†Divisions of Renal Medicine, and Baxter Novum, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olof Heimburger
†Divisions of Renal Medicine, and Baxter Novum, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Barany
†Divisions of Renal Medicine, and Baxter Novum, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Stenvinkel
†Divisions of Renal Medicine, and Baxter Novum, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan J. Carrero
†Divisions of Renal Medicine, and Baxter Novum, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden; and
‡Center for Molecular Medicine and
§Center for Gender Medicine, Karolinska Institute, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: juan.jesus.carrero@ki.se
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Summary

Background and objectives Conflicting evidence exists with regard to the association of thyroid hormones and mortality in dialysis patients. This study assesses the association between basal and trimestral variation of thyroid stimulating hormone, triiodothyronine, and thyroxine and mortality.

Design, setting, participants, & measurements In 210 prevalent hemodialysis patients, serum triiodothyronine, thyroxine, thyroid stimulating hormone, and interleukin-6 were measured 3 months apart. Cardiovascular and non-cardiovascular deaths were registered during follow-up. Based on fluctuations along tertiles of distribution, four trimestral patterns were defined for each thyroid hormone: persistently low, decrease, increase, and persistently high. The association of baseline levels and trimestral variation with mortality was investigated with Kaplan–Meier curves and Cox proportional hazard models.

Results During follow-up, 103 deaths occurred. Thyroid stimulating hormone levels did not associate with mortality. Patients with relatively low basal triiodothyronine concentrations had higher hazards of dying than patients with high levels. Longitudinally, patients with persistently low levels of triiodothyronine during the 3-month period had higher mortality hazards than those having persistently high levels. These associations were mainly attributable to cardiovascular-related mortality. The association between thyroxine and mortality was not altered after adjustment for triiodothyronine.

Conclusions Hemodialysis patients with reduced triiodothyronine or thyroxine levels bear an increased mortality risk, especially due to cardiovascular causes. This was true when considering both baseline measurements and trimestral variation patterns. Our longitudinal design adds observational evidence supporting the hypothesis that the link may underlie a causal effect.

Introduction

A reduction in kidney function encompasses a number of alterations in thyroid hormone metabolism that renders a particular “non-thyroidal illness” syndrome (1) in patients with CKD, where low levels of both total triiodothyronine (T3) and free triiodothyronine (fT3) are hallmark findings. Recent reports suggest that as many as 70% of patients with ESRD present with low T3 levels (2–5) and as many as 20%–25% have subclinical hypothyroidism (6,7). The underlying pathophysiology of these derangements is likely multifactorial, involving iodine retention, altered serum protein binding capacity, systemic inflammation, and peripheral deiodinase activity (8,9).

These abnormalities have traditionally been considered as a physiologic mechanism to save energy in response to uremic wasting (10). However, growing evidence suggests participation of T3 in the pathophysiology of endothelial dysfunction (11), atherosclerosis (12), and cardiac abnormalities (13) of CKD patients. Some studies, with somewhat conflicting results, have also implicated thyroid alterations in the mortality risk of CKD patients (14–16). Zoccali et al. (14) were the first to report a direct association between low fT3 and all-cause mortality in stable hemodialysis (HD) patients, with similar findings in peritoneal dialysis patients (17). We could further confirm and expand these observations in a cohort of euthyroid incident HD patients, in which the variance of all-cause and cardiovascular (CV) mortality was better explained by T3 than by fT3 levels (16). In contrast, a study in 87 HD patients could not confirm these findings (15), and a retrospective report found that the association between fT3 and mortality was confounded by the nutritional status of the patients (5). Whereas existing evidence on the association between thyroid hormones and mortality is limited to studies considering single measurements of hormone levels, it is currently unknown whether thyroid hormone fluctuation over time affects mortality hazards. In apparently healthy individuals, thyroid hormone concentrations show a narrow intraindividual variation (18), although certain circadian and seasonal (mainly due to seasonal differences in iodine intake) fluctuations have been observed (19). In diseased individuals, however, thyroid hormone concentrations seem subjected to a higher fluctuation as influenced among others by wasting syndromes, persistent inflammation, and cardiac comorbidities (19). Against this background, the objective of our study was to evaluate the association between both basal levels and longitudinal (3-month) variation of T3, thyroxine (T4), and thyroid stimulating hormone (TSH) and all-cause and cause-specific mortality. We did so in a well-defined cohort of maintenance HD patients.

Materials and Methods

The Medical Ethics Committee at Karolinska University Hospital and Uppsala University approved the study protocol, and patients consented to participate. This is a post hoc analysis from a cohort of prevalent HD patients in the Stockholm region, described elsewhere in more detail (20,21). The inclusion period ranged from October 2003 until September 2004. Of 224 patients originally included in this cohort, TSH, T3, and T4 were not measured in six individuals due to limited plasma. The patients were on angiotensin-converting enzyme inhibitors and∕or angiotensin II receptor antagonists (n=72), β-blockers (n=109), calcium-channel blockers (n=57), diuretics (n=104), statins (n=72), antiplatelet drugs (n=65), erythropoiesis-stimulating agents (n=211), and iron substitution (n=144). Sixteen patients were receiving levothyroxine, and one of these additionally used amiodarone. No patients were receiving lithium or propranolol. Comorbidity was classified according to Davies et al. (22) on a 7-point scale that was simplified into a three-risk-category scale. Nutritional status was evaluated with the subjective global assessment.

From inclusion onward, patients were followed for the occurrence of fatal events. Causes of death were retrieved from death certificates and classified as CV or non-CV. CV mortality was defined as death due to myocardial ischemia or infarction, cardiac arrest or unknown sudden death, acute and chronic heart failure, cerebrovascular accidents, cerebral hemorrhage, and ruptured aortic aneurysm. Non-CV death was defined as that not attributable to a CV origin. Individuals with unknown causes of death (n=13) were grouped within the non-CV group.

Biochemical Methods

Venous blood samples were drawn and stored at −70°C if not analyzed immediately. Concentrations of high-sensitivity C-reactive protein (CRP) and serum albumin (bromcresol purple) were determined using routine methods at the Department of Laboratory Medicine, Karolinska University Hospital (Huddinge, Sweden). Serum IL-6 concentrations were quantified in an automated Immulite analyzer (Siemens Healthcare Diagnostics, Los Angeles, CA). Thyroid hormones levels were assessed on an Immulite system, using commercially available immunometric assays for T3 (analytical sensitivity [AS], 0.54 nmol/L; total coefficient of variation [CoV], 13.2% and 5.4% at the levels of 0.95 and 6.02 nmol/L), T4 (AS, 5 nmol/L; total CoV, 8.4% and 6.3% at the levels of 49 and 167 nmol/L), and TSH (AS, 0.004 mIU/L; total CoV, 12.5% and 4.6% at the levels of 0.016 and 1.3 mIU/L). Results are expressed as the average of two measurements.

Statistical Analyses

Low T3 or T4 categories were defined as those below the 66th percentile of distribution (higher tertile as the reference group). For the analysis of trimestral thyroid hormone variation, we classified patients according to their shift along tertile distribution at each time point, a strategy described in more detail elsewhere (23). From the nine possible combinations, four groups were created by clustering patients with changes in the same direction: (1) individuals who showed a change to lower tertiles were classified as the “decrease” group, (2) individuals showing an increase to upper tertiles were assigned to the “increase” group, (3) individuals with both values within the highest tertile of distribution were labeled as a “persistently high” group, and (4) individuals with both values within the lower or the middle tertile were labeled as a “persistently low” group. Differences between groups were tested by means of parametric (independent sample t test, one-way ANOVA), non-parametric (Mann–Whitney U and Kruskal–Wallis test), and chi-squared tests as appropriate. Correlation was assessed by means of Pearson or Spearman tests, as appropriate. Survival during follow-up was analyzed by the Kaplan–Meier method, and hazard ratios (HRs) were calculated with Cox proportional hazard models with different degrees of adjustment. Age, sex, comorbidities, protein-energy wasting, albumin, smoking, levothyroxine prescription, dialysis vintage, and IL-6 were considered possible confounders. T3, IL-6, and vintage on dialysis were logarithmically transformed because of non-normal distribution. In order to test whether the effect of T4 levels at baseline and variation groupings on mortality was due to the effect of T3, we performed an additional adjustment for log T3 or δ T3, respectively.

As a sensitivity analysis, Cox analyses were repeated in biochemically euthyroid patients only, defined as presenting with normal TSH (reference range 0.1–4.5 mIU/L) and T4 (reference range 57.9–169.9 nmol/L). Cox analyses were adjusted by CRP instead of IL-6 as a surrogate of inflammation. HRs with 95% confidence intervals (95% CIs) not including one were considered to be statistically significant. P values <0.05 were considered statistically significant. SPSS version 17.0 (SPSS Inc., Chicago, IL) was used to analyze the study material.

Results

Basal Thyroid Hormone Levels and Its Association with Mortality

In all 218 individuals, median (interquartile range; IQR) levels of TSH and T3 were 1.35 (0.84–2.52) mIU/L and 0.82 (0.67–1.03) nmol/L, respectively. Basal T4 levels were on average (SD) 70.44 (24.65) nmol/L and positively related to T3 levels (ρ=0.529, P<0.001). Thyroid hormone disorders on the basis of circulating hormones were common: 146 patients were classified as having a low T3 syndrome, 11 patients were classified as having overt hypothyroidism, and an additional 4 patients were classified as having subclinical hypothyroidism. General and thyroid-specific characteristics of studied patients are presented in Table 1, according to low levels of T3 (≤66th percentile; ≤0.94 nmol/L) and T4 (≤66th percentile; ≤77.2 nmol/L). Patients with low T3 presented with a higher prevalence of comorbidities, increased IL-6 levels, and lower T4 concentrations. Patients with low T4 were more often male, malnourished, and presenting with lower T3 levels. In univariate analyses, IL-6 positively associated with TSH (Spearman rank test ρ=0.16, P=0.01) and negatively with T3 (ρ = −0.17, P=0.009). CRP levels positively associated with T4 (ρ=0.19, P=0.003). During a median (IQR) follow-up period of 38.2 (17.6–45.1) months, 103 deaths occurred (40 CV and 63 non-CV) of which 77 occurred in the low T3 group and 26 in the high T3 group. As shown in Table 2, the crude and adjusted hazards of dying (by all causes) were 1.8 and 1.6 times higher, respectively, in patients with low T3 levels than in those with high T3 levels. This was mainly due to CV deaths, where HRs were considerably higher in magnitude (crude HR [95%CI]: 2.8 [1.2–6.4]) and remained so after adjustment for confounders (adjusted HR: 2.7 [1.2–6.3]). A similar analysis was performed for T4. A statistically significant association between low T4 levels and an increased all-cause and CV mortality was observed after adjustment for confounders (adjusted HR: 3.0 [1.3–6.8]). Further adjustment for log-T3 levels did not materially alter the strength of these associations, although a 16% reduction in magnitude was observed for CV mortality. Neither low T3 nor low T4 levels were significantly associated with non-CV mortality. TSH levels did not associate with any outcome measure (data not shown).

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics according to T3 and T4 dichotomization in 218 prevalent hemodialysis patients

View this table:
  • View inline
  • View popup
Table 2.

Mortality HRs and 95% CIs according to basal T3 and T4 in 218 prevalent hemodialysis patients

Trimestral Thyroid Hormone Variation and Its Association with Mortality

Thyroid hormones were assessed again after 3 months in 210 patients. Median (IQR) coefficients of intrapatient variation were as follows: T3, 7.8% (2.6–12.5); T4, 7.1% (4.0–12.0); and TSH, 14.0% (5.4–24.8). In Table 3, general and thyroid-specific characteristics are depicted across four different T3 variation groups (Materials and Methods), not observing major differences among these groups. The same was true for T4 variation groups (data not shown). In univariate correlation analyses, δ TSH associated with δ IL-6 (ρ=0.17, P=0.01), whereas δ T3 associated with δ serum albumin (ρ=0.22, P=0.01). Figure 1 shows the Kaplan–Meier curves for T3 and T4 trimestral variation, both being associated with patient outcome. Table 4 shows crude and adjusted Cox models. Patients with persistently low T3 levels presented the highest hazard for all-cause mortality (HR: 2.7 [1.5–5.0]) compared with that of subjects having persistently high levels. This was particularly true for the association with CV mortality (HR: 4.0 [1.3–11.7]), whereas no association between T3 variation and non-CV mortality was observed (data not shown). Adjustment for confounders did not alter either the magnitude of the association or the statistical significance. Of note, elevated HRs, albeit statistically non-significant, were observed for patients showing increases or decreases of T3 levels during the 3-month follow-up compared with those of patients having persistently high concentrations.

View this table:
  • View inline
  • View popup
Table 3.

General characteristics according to T3 trimestral variation in 210 prevalent hemodialysis patients

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan–Meier curves for T3 and T4 trimestral variation. Kaplan–Meier survival curves for all-cause mortality according to T3 (A) and T4 (B) trimestral variation in 210 prevalent hemodialysis patients.

View this table:
  • View inline
  • View popup
Table 4.

Mortality HRs and 95% Cis according to T3 and T4 trimestral variation in 210 prevalent hemodialysis patients

Patients with persistently low T4 levels showed elevated hazards for all-cause mortality compared with those of patients having persistently high T4 levels, an association that reached statistical significance after adjustment for confounders. Higher hazards were observed for prediction of CV mortality (crude HR: 2.6 [1.0–7.0]). In both cases, further adjustment for trimestral T3 variation (as a continuous variable) did not significantly affect the results. Of note, a decrease in T4 was also associated with elevated hazards for CV mortality. No association was observed between T4 variation patterns and non-CV mortality.

Trimestral TSH variation patterns were not associated with outcome. In a sensitivity analysis, all baseline and longitudinal Cox analyses were repeated in biochemically euthyroid patients only (n=210 at baseline, n=202 with available data at both time points). Additionally, Cox adjustment was done with CRP instead of IL-6. In both cases, results were not different (data not shown).

Discussion

In this study, we show that both basal levels and trimestral variation of T3 and T4 are associated with increased mortality, particularly due to CV causes. Adjusting in the causal pathway suggests that the mechanisms associating low T4 levels with an elevated mortality rate may be, at least in part, independent of T3 levels.

Our observation linking low basal T3 levels with increased all-cause mortality is in agreement with most (5,14,16,17) but not all (15) preceding literature. Whereas earlier studies (5,14,17) only studied the association between T3 and fT3 and all-cause mortality, our study adds that this mortality prediction is mainly attributable to CV causes. The lack of mortality prediction observed by Fernández-Reyes et al. (15) could relate to the selection of patients having survived at least 12 months, the low number of events encountered, and the strict inclusion criteria that excluded, among others, patients with abnormal fT3 and free T4 (fT4) levels. In this sense, our analysis shows that patients with both baseline and longitudinal low T3 levels have a relatively shorter time to death, possibly suggesting a stronger impact of thyroid hormones on short-term outcome. The study from Ozen et al. (5) showed that adjustment for CRP and s-albumin abrogated the association between fT3 and all-cause mortality, and the authors concluded that poor nutritional status confounded this association. The acute-phase reactant nature of s-albumin makes these results difficult to contextualize (24,25), and in our study, adjustment for inflammation (IL-6) and malnutrition did not affect this association. Furthermore, Zoccali et al. (14) reported that as adjustment for fT3 abrogated the association between inflammation and patient outcome, fT3 may be an intermediate pathologic indicator of systemic inflammation. In our data, as well as in Ozen et al. (5), adjustment for inflammation did not affect the link between T3 and mortality. Also, associations between trimestral thyroid hormone changes and variation of inflammatory markers were somewhat weak and inconsistent in our study. One limitation that makes these studies not fully comparable is that whereas Zoccali et al. (14) and Ozen et al. (5) measured free fractions, we report on total T4 and T3 levels only. Although adjustment for s-albumin (one of the main transporters of T3 in plasma) did not modify the observed associations, we should acknowledge that fT3 is not tantamount to T3. Several studies have, nevertheless, suggested anti-atherosclerotic effects of fT3 on the vascular bed via its effect on mitochondrial oxidative systems, induction of vasodilatory molecules, inhibition of angiotensin II receptor expression and inhibition of downstream signal transduction, mechanisms all of which do not necessarily involve the inflammatory cascade (26–28).

In support of the association between T3 and cardiovascular death in our study, a previous report (11) in patients with moderate to severe kidney disease reported that T3 levels inversely associated with flow-mediated vasodilation and that this observation was dependent on multivariate adjustment for asymmetric dimethylarginine levels. At a cardiac level, low T3 levels in CKD patients are associated with reduced left ventricular function, increased left ventricular mass (13), and elevated intima–media thickness (12). Our study also adds novel evidence regarding the association between trimestral T3 variation and all-cause and CV mortality in ESRD. Patients with persistently low T3 levels exhibited the highest hazards of dying. Notably, also increased variability in T3 (e.g., both increases and decreases in concentration) resulted in elevated hazards albeit statistically not significant, leading us to hypothesize that T3 fluctuations may link to adverse outcomes. This finding accords with a previous study in critically ill patients (29), in which a fast decline in T3 and T4 (without a concomitant rise in TSH levels) was observed prior to death. Our longitudinal analysis, by including two observations 3 months apart in the same individual, represents a step forward by virtue of observing the subject-specific temporal order of events. What factors drive this, and whether uremic thyroid fluctuation is higher than in other diseases remains, for now, unknown.

Another novelty in our analysis is the association between baseline and trimestral variation of T4 levels with (CV) mortality. Although this is the first study to report so in a dialysis population, the findings are in line with previous evidence in non-renal patients with non-thyroidal illness (29,30). An interesting aspect of our analysis is that the strength of the association between low T4 levels and mortality was not fully affected by adjustment for T3. This may suggest that the effect of T4 on outcome is, at least in part, not dependent on its metabolite and that both may participate in the increased CV risk. According to recent literature, however, adjusting in the causal pathway may not be so straightforward as initially thought (31), and caution is needed in the interpretation of this finding, which warrants confirmation in further studies. Nevertheless, our previous report in incident dialysis patients also observed, by means of receiving operator characteristics analysis, a significant association between T4 levels and mortality (16). The study by Takamura et al. (32) in euthyroid patients demonstrated that carotid intima–media thickness was inversely and independently associated with T4 and fT4, suggesting an increased CV risk in subjects with low T4 even within the normal reference range. Differential effects of T4 and T3 on immune cells have also been reported: T4 stimulated whereas T3 inhibited peripheral lymphocyte proliferation (33).

In the interpretation of our results, some additional limitations must be addressed: Causes of death were extracted by death records and not confirmed by autopsies, which could result in misclassification. As unknown causes of death were denoted as non-CV, this could translate, in any case, into an underestimation of the observed effect toward the null hypothesis, and the true hazards may possibly be larger. The inclusion of prevalent dialysis patients may infer into a survival bias, although preceding studies contemplate also prevalent patients in their designs. Finally, ours is an observational study, and confounding by unmeasured factors cannot be ruled out.

To conclude, patients with reduced T3 and/or T4 levels bear an increased mortality risk, especially due to CV causes. This was true when considering both baseline measurements and trimestral variation patterns. Our longitudinal design adds important observational evidence—although nondecisive—that the link may underlie a causal effect.

Disclosures

B.L. is employed by Baxter Healthcare Corporation.

Acknowledgments

We thank the patients and personnel involved in the creation of this cohort. Also, we are indebted to our research staff at KBC (Annika Nilsson, Ann-Christin Emmoth, and Ulrika Jensen) and KFC (Bjorn Anderstam, Monica Eriksson, and Ann-Christin Bragfors-Helin).

The collection of this cohort was supported by a grant from Amgen. We acknowledge support from the Loo and Hans Ostermans’ Foundation, the Westman’s Foundation, and the Swedish Research Council. Baxter Novum is the result of a grant from Baxter Healthcare Corporation to the Karolinska Institute.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related editorial, “Thyroid Function and Clinical Outcomes in Kidney Failure,” on pages 12–14.

  • Access to UpToDate on-line is available for additional clinical information at www.cjasn.org.

  • Received May 31, 2011.
  • Accepted October 3, 2011.
  • Copyright © 2012 by the American Society of Nephrology

References

  1. ↵
    1. Warner MH,
    2. Beckett GJ
    : Mechanisms behind the non-thyroidal illness syndrome: An update. J Endocrinol 205: 1–13, 2010pmid:20016054
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Kaptein EM,
    2. Quion-Verde H,
    3. Chooljian CJ,
    4. Tang WW,
    5. Friedman PE,
    6. Rodriquez HJ,
    7. Massry SG
    : The thyroid in end-stage renal disease. Medicine (Baltimore) 67: 187–197, 1988pmid:3259281
    OpenUrlCrossRefPubMed
    1. Lim VS,
    2. Fang VS,
    3. Katz AI,
    4. Refetoff S
    : Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine. J Clin Invest 60: 522–534, 1977pmid:408377
    OpenUrlPubMed
    1. Song SH,
    2. Kwak IS,
    3. Lee DW,
    4. Kang YH,
    5. Seong EY,
    6. Park JS
    : The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant 24: 1534–1538, 2009pmid:19106286
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ozen KP,
    2. Asci G,
    3. Gungor O,
    4. Carrero JJ,
    5. Kircelli F,
    6. Tatar E,
    7. Sevinc Ok E,
    8. Ozkahya M,
    9. Toz H,
    10. Cirit M,
    11. Basci A,
    12. Ok E
    : Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol 33: 305–312, 2011pmid:21389695
    OpenUrlCrossRefPubMed
  4. ↵
    1. Chonchol M,
    2. Lippi G,
    3. Salvagno G,
    4. Zoppini G,
    5. Muggeo M,
    6. Targher G
    : Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1296–1300, 2008pmid:18550654
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Lo JC,
    2. Chertow GM,
    3. Go AS,
    4. Hsu CY
    : Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int 67: 1047–1052, 2005pmid:15698444
    OpenUrlCrossRefPubMed
  6. ↵
    1. Zoccali C,
    2. Tripepi G,
    3. Cutrupi S,
    4. Pizzini P,
    5. Mallamaci F
    : Low triiodothyronine: A new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 16: 2789–2795, 2005pmid:16033857
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Iglesias P,
    2. Díez JJ
    : Thyroid dysfunction and kidney disease. Eur J Endocrinol 160: 503–515, 2009pmid:19095779
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Chopra IJ
    : Nonthyroidal illness syndrome or euthyroid sick syndrome? Endocr Pract 2: 45–52, 1996pmid:15251561
    OpenUrlPubMed
  9. ↵
    1. Yilmaz MI,
    2. Sonmez A,
    3. Karaman M,
    4. Ay SA,
    5. Saglam M,
    6. Yaman H,
    7. Kilic S,
    8. Eyileten T,
    9. Caglar K,
    10. Oguz Y,
    11. Vural A,
    12. Yenicesu M,
    13. Zoccali C
    : Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol 33: 25–32, 2011pmid:21150192
    OpenUrlPubMed
  10. ↵
    1. Tatar E,
    2. Kircelli F,
    3. Asci G,
    4. Carrero JJ,
    5. Gungor O,
    6. Demirci MS,
    7. Ozbek SS,
    8. Ceylan N,
    9. Ozkahya M,
    10. Toz H,
    11. Ok E
    : Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol 6: 2240–2246, 2011
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Zoccali C,
    2. Benedetto F,
    3. Mallamaci F,
    4. Tripepi G,
    5. Cutrupi S,
    6. Pizzini P,
    7. Malatino LS,
    8. Bonanno G,
    9. Seminara G
    : Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. J Hypertens 24: 2039–2046, 2006pmid:16957565
    OpenUrlCrossRefPubMed
  12. ↵
    1. Zoccali C,
    2. Mallamaci F,
    3. Tripepi G,
    4. Cutrupi S,
    5. Pizzini P
    : Low triiodothyronine and survival in end-stage renal disease. Kidney Int 70: 523–528, 2006pmid:16775599
    OpenUrlPubMed
  13. ↵
    1. Fernández-Reyes MJ,
    2. Diez JJ,
    3. Collado A,
    4. Iglesias P,
    5. Bajo MA,
    6. Estrada P,
    7. Del Peso G,
    8. Heras M,
    9. Molina A,
    10. Selgas R
    : Are low concentrations of serum triiodothyronine a good marker for long-term mortality in hemodialysis patients? Clin Nephrol 73: 238–240, 2010pmid:20178724
    OpenUrlCrossRefPubMed
  14. ↵
    1. Carrero JJ,
    2. Qureshi AR,
    3. Axelsson J,
    4. Yilmaz MI,
    5. Rehnmark S,
    6. Witt MR,
    7. Bárány P,
    8. Heimbürger O,
    9. Suliman ME,
    10. Alvestrand A,
    11. Lindholm B,
    12. Stenvinkel P
    : Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 262: 690–701, 2007pmid:17908160
    OpenUrlCrossRefPubMed
  15. ↵
    1. Enia G,
    2. Panuccio V,
    3. Cutrupi S,
    4. Pizzini P,
    5. Tripepi G,
    6. Mallamaci F,
    7. Zoccali C
    : Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 22: 538–544, 2007pmid:17082213
    OpenUrlCrossRefPubMed
  16. ↵
    1. Andersen S,
    2. Pedersen KM,
    3. Bruun NH,
    4. Laurberg P
    : Narrow individual variations in serum T(4) and T(3) in normal subjects: A clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 87: 1068–1072, 2002pmid:11889165
    OpenUrlCrossRefPubMed
  17. ↵
    1. Karmisholt J,
    2. Andersen S,
    3. Laurberg P
    : Variation in thyroid function in subclinical hypothyroidism: Importance of clinical follow-up and therapy. Eur J Endocrinol 164: 317–323, 2011pmid:21208994
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Snaedal S,
    2. Heimbürger O,
    3. Qureshi AR,
    4. Danielsson A,
    5. Wikström B,
    6. Fellström B,
    7. Fehrman-Ekholm I,
    8. Carrero JJ,
    9. Alvestrand A,
    10. Stenvinkel P,
    11. Bárány P
    : Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: Implications for patient survival. Am J Kidney Dis 53: 1024–1033, 2009pmid:19394732
    OpenUrlCrossRefPubMed
  19. ↵
    1. Carrero JJ,
    2. Qureshi AR,
    3. Axelsson J,
    4. Avesani CM,
    5. Suliman ME,
    6. Kato S,
    7. Bárány P,
    8. Snaedal-Jonsdottir S,
    9. Alvestrand A,
    10. Heimbürger O,
    11. Lindholm B,
    12. Stenvinkel P
    : Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 85: 695–701, 2007pmid:17344489
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Davies SJ,
    2. Phillips L,
    3. Naish PF,
    4. Russell GI
    : Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 17: 1085–1092, 2002pmid:12032201
    OpenUrlCrossRefPubMed
  21. ↵
    1. Meuwese CL,
    2. Snaedal S,
    3. Halbesma N,
    4. Stenvinkel P,
    5. Dekker FW,
    6. Qureshi AR,
    7. Barany P,
    8. Heimburger O,
    9. Lindholm B,
    10. Krediet RT,
    11. Boeschoten EW,
    12. Carrero JJ
    : Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-α are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 26: 1313–1318, 2011pmid:20846939
    OpenUrlCrossRefPubMed
  22. ↵
    1. Friedman AN,
    2. Fadem SZ
    : Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol 21: 223–230, 2010pmid:20075063
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. de Mutsert R,
    2. Grootendorst DC,
    3. Indemans F,
    4. Boeschoten EW,
    5. Krediet RT,
    6. Dekker FW
    Netherlands Cooperative Study on the Adequacy of Dialysis-II Study Group: Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr 19: 127–135, 2009pmid:19218039
    OpenUrlCrossRefPubMed
  24. ↵
    1. Fukuyama K,
    2. Ichiki T,
    3. Takeda K,
    4. Tokunou T,
    5. Iino N,
    6. Masuda S,
    7. Ishibashi M,
    8. Egashira K,
    9. Shimokawa H,
    10. Hirano K,
    11. Kanaide H,
    12. Takeshita A
    : Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. Hypertension 41: 598–603, 2003pmid:12623965
    OpenUrlAbstract/FREE Full Text
    1. Costantini F,
    2. Pierdomenico SD,
    3. De Cesare D,
    4. De Remigis P,
    5. Bucciarelli T,
    6. Bittolo-Bon G,
    7. Cazzolato G,
    8. Nubile G,
    9. Guagnano MT,
    10. Sensi S,
    11. Cuccurullo F,
    12. Mezzetti A
    : Effect of thyroid function on LDL oxidation. Arterioscler Thromb Vasc Biol 18: 732–737, 1998pmid:9598831
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Fukuyama K,
    2. Ichiki T,
    3. Imayama I,
    4. Ohtsubo H,
    5. Ono H,
    6. Hashiguchi Y,
    7. Takeshita A,
    8. Sunagawa K
    : Thyroid hormone inhibits vascular remodeling through suppression of cAMP response element binding protein activity. Arterioscler Thromb Vasc Biol 26: 2049–2055, 2006pmid:16794221
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. McLarty DG,
    2. Ratcliffe WA,
    3. McColl K,
    4. Stone D,
    5. Ratcliffe JG
    : Letter: Thyroid-hormone levels and prognosis in patients with serious non-thyroidal illness. Lancet 2: 275–276, 1975pmid:49813
    OpenUrlPubMed
  27. ↵
    1. Slag MF,
    2. Morley JE,
    3. Elson MK,
    4. Crowson TW,
    5. Nuttall FQ,
    6. Shafer RB
    : Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 245: 43–45, 1981pmid:7431627
    OpenUrlCrossRefPubMed
  28. ↵
    1. Hafeman DM,
    2. Schwartz S
    : Opening the black box: A motivation for the assessment of mediation. Int J Epidemiol 38: 838–845, 2009pmid:19261660
    OpenUrlCrossRefPubMed
  29. ↵
    1. Takamura N,
    2. Akilzhanova A,
    3. Hayashida N,
    4. Kadota K,
    5. Yamasaki H,
    6. Usa T,
    7. Nakazato M,
    8. Maeda T,
    9. Ozono Y,
    10. Aoyagi K
    : Thyroid function is associated with carotid intima-media thickness in euthyroid subjects. Atherosclerosis 204: e77–e81, 2009pmid:18977482
    OpenUrlCrossRefPubMed
  30. ↵
    1. Kruger TE
    : Immunomodulation of peripheral lymphocytes by hormones of the hypothalamus-pituitary-thyroid axis. Adv Neuroimmunol 6: 387–395, 1996pmid:9183518
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 7 (1)
Clinical Journal of the American Society of Nephrology
Vol. 7, Issue 1
January 13, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Baseline Levels and Trimestral Variation of Triiodothyronine and Thyroxine and Their Association with Mortality in Maintenance Hemodialysis Patients
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Baseline Levels and Trimestral Variation of Triiodothyronine and Thyroxine and Their Association with Mortality in Maintenance Hemodialysis Patients
Christiaan L. Meuwese, Friedo W. Dekker, Bengt Lindholm, Abdul R. Qureshi, Olof Heimburger, Peter Barany, Peter Stenvinkel, Juan J. Carrero
CJASN Jan 2012, 7 (1) 131-138; DOI: 10.2215/CJN.05250511

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Baseline Levels and Trimestral Variation of Triiodothyronine and Thyroxine and Their Association with Mortality in Maintenance Hemodialysis Patients
Christiaan L. Meuwese, Friedo W. Dekker, Bengt Lindholm, Abdul R. Qureshi, Olof Heimburger, Peter Barany, Peter Stenvinkel, Juan J. Carrero
CJASN Jan 2012, 7 (1) 131-138; DOI: 10.2215/CJN.05250511
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Summary
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

ESRD and Chronic Dialysis

  • Immunogenicity of Augmented Compared With Standard Dose Hepatitis B Vaccine in Pediatric Patients on Dialysis: a Midwest Pediatric Nephrology Consortium Study
  • Changes in the Profile of Endovascular Procedures Performed in Freestanding Dialysis Access Centers over 15 Years
  • Prognostic Value of Residual Urine Volume, GFR by 24-hour Urine Collection, and eGFR in Patients Receiving Dialysis
Show more ESRD and Chronic Dialysis

Cited By...

  • Low Triiodothyronine Syndrome and Long-Term Cardiovascular Outcome in Incident Peritoneal Dialysis Patients
  • Low-T3 Syndrome in Peritoneal Dialysis: Metabolic Adaptation, Marker of Illness, or Mortality Mediator?
  • The impact of low triiodothyronine levels on mortality is mediated by malnutrition and cardiac dysfunction in incident hemodialysis patients
  • Hypothyroidism and Mortality among Dialysis Patients
  • Thyroid Function and Clinical Outcomes in Kidney Failure
  • Google Scholar

Similar Articles

Related Articles

  • Thyroid Function and Clinical Outcomes in Kidney Failure
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire